Radiation dose escalation combined with hormone therapy improves outcome in localised prostate cancer

Authors

  • Ása Karlsdottir Section of Oncology, Institute of Medicine, Medical Faculty, University of Bergen, N-5021, Bergen, Norway; Department of Oncology and Medical Physics, Haukeland University Hospital, N-5021, Bergen, Norway
  • Ludvig Paul Muren Section of Oncology, Institute of Medicine, Medical Faculty, University of Bergen, N-5021, Bergen, Norway; Department of Oncology and Medical Physics, Haukeland University Hospital, N-5021, Bergen, Norway
  • Tore Wentzel-Larsen Centre for Clinical Research, Haukeland University Hospital, N-5021, Bergen, Norway
  • Dag C. Johannessen Department of Oncology and Medical Physics, Haukeland University Hospital, N-5021, Bergen, Norway
  • August Bakke Department of Urology, Haukeland University Hospital, N-5021, Bergen, Norway
  • Per Øgreid Department of Urology, Stavanger University Hospital, Stavanger, Norway
  • Ole Johan Halvorsen Department of Pathology, The Gade Institute, Haukeland University Hospital, N-5021, Bergen, Norway
  • Olav Dahl Section of Oncology, Institute of Medicine, Medical Faculty, University of Bergen, N-5021, Bergen, Norway; Department of Oncology and Medical Physics, Haukeland University Hospital, N-5021, Bergen, Norway

DOI:

https://doi.org/10.1080/02841860500468943

Abstract

We present the impact of systematic radiation dose escalation from 64 Gy to 66 Gy to 70 Gy on the outcome after radiation therapy (RT) alone or combined with hormonal treatment (HT) in a series of 494 consecutive localised prostate cancer patients treated during 1990–1999. Prognostic factors for prostate-specific antigen (PSA) failure, overall survival (OS) and prostate cancer specific survival (CSS) were investigated using multivariate analysis. T stage, pre-treatment PSA, grade, radiation dose and HT were found to be independent predictors of PSA failure. T stage, grade and HT were also independent predictors of both OS and CSS, while radiation dose was a significant predictor for OS and indicated a trend (p = 0.07) for CSS. A dose of 70 Gy combined with hormonal treatment improves PSA failure free survival and survival in localised prostate cancer compared with doses of 64–66 Gy.

Downloads

Download data is not yet available.

Downloads

Published

2006-01-01

How to Cite

Karlsdottir, Ása, Paul Muren, L., Wentzel-Larsen, T., Johannessen, D. C., Bakke, A., Øgreid, P., … Dahl, O. (2006). Radiation dose escalation combined with hormone therapy improves outcome in localised prostate cancer. Acta Oncologica, 45(4), 454–462. https://doi.org/10.1080/02841860500468943

Issue

Vol. 45 No. 4 (2006): Acta Oncologica

Section

Articles